For nearly a century, science held that mammalian cells could not survive without a specific chemical system to produce cysteine — a molecule as fundamental to life as breath. Then a colony of mice in Montana simply refused to die as expected, and nine years of patient inquiry later, researchers have uncovered a hidden backup pathway cells use to sustain themselves when the standard route fails. The discovery, published in Nature Chemical Biology, not only rewrites a foundational assumption of cell biology but opens a new front in the long effort to make cancer treatments more effective.
Scientists uncover hidden cellular survival pathway that cancer cells may exploit
This was supposed to be impossible.
Mark
So scientists found that cells can make cysteine without the system everyone thought was essential. How did they even stumble onto this?
Mimi
Schmidt had engineered mice that shouldn't have survived—they lacked both known ways to convert cystine into cysteine. But they lived. That contradiction was the crack that opened everything.
Luke
Wait—how long did those mice live? Was this a short-term survival or did they thrive?
Mimi
The source doesn't specify the lifespan or health status of the mice. We know they survived conditions thought to be fatal, but the details of how long and how well aren't in the paper summary.
Mark
And then it took seven more years to figure out what was actually happening?
Mimi
Yes. They needed collaborators with specialized analytical tools to trace the actual chemical pathway. Hungarian researchers helped identify that cells were breaking a different bond in cystine to free the cysteine.
Luke
So this is a real alternative route, not just cells limping along on fumes?
Mimi
It appears to be a functional pathway, yes. The cells were obtaining usable cysteine through it. But again, the source doesn't detail how efficient it is compared to the standard system.
Mark
The cancer angle—that's the part that could matter clinically. Are they saying cancer cells definitely use this pathway to resist treatment?
Mimi
They suspect it. Schmidt says cancer cells "may use" this backup pathway to survive chemotherapy and other treatments. It's a hypothesis grounded in the biology, but not yet proven in tumor cells.
Luke
That's an important distinction. The discovery itself is solid—the backup pathway exists. But whether blocking it in cancer will actually work is still theoretical.
Mimi
Exactly. The next step would be developing a way to selectively shut down this pathway in tumors without harming healthy cells. That's the real challenge ahead.
Mark
How many people worked on this?
Mimi
Schmidt led it, with Nagy's team in Budapest. Several undergraduates and a doctoral student at Montana State contributed significantly—Seaford and Austad were co-first authors while still undergrads.
El Pulso
- Mice engineered to lack both known cellular survival systems lived anyway in 2014, quietly invalidating a near-century-old assumption that had never been seriously questioned.
- The contradiction was urgent enough that a Montana geneticist and Hungarian oncology researchers spent nine years tracing an invisible chemical detour hidden inside the cell's own machinery.
- What they found is a second way cells can break apart cystine to free usable cysteine — a carbon-sulfur bond no one had thought to look at, exploited by life long before modern biology arrived to observe it.
- Cancer cells appear to be using this same ancient backup route to outlast chemotherapy, radiation, and immunotherapy, quietly regrowing after treatments that should have overwhelmed them.
- The path forward is now visible: selectively disabling this pathway in tumor cells could strip away a hidden layer of their resilience, making existing treatments significantly more lethal to cancer while sparing healthy tissue.
For nearly a century, science held that mammalian cells could not survive without a specific chemical system to produce cysteine — a molecule as fundamental to life as breath. Then a colony of mice in Montana simply refused to die as expected, and nine years of patient inquiry later, researchers have uncovered a hidden backup pathway cells use to sustain themselves when the standard route fails. The discovery, published in Nature Chemical Biology, not only rewrites a foundational assumption of cell biology but opens a new front in the long effort to make cancer treatments more effective.
For nearly a century, cell biologists held a firm conviction: mammalian cells cannot survive without at least one functioning disulfide reductase system, the machinery that converts cystine into cysteine — an amino acid essential for building proteins and defending against cellular damage. No organism had ever been observed living without it. The assumption seemed unassailable.
Then in 2014, geneticist Ed Schmidt at Montana State University watched a colony of engineered mice survive conditions that theory said should have killed them. Their liver cells lacked both known disulfide reductase systems entirely. The mice lived anyway. Schmidt had seen unusual physiological responses in earlier mouse lines missing only one system, and the accumulating evidence suggested the foundational belief might simply be wrong.
Seven more years of work followed. Schmidt's team joined forces with Peter Nagy and colleagues at the Hungarian National Institute of Oncology in Budapest, whose analytical expertise proved essential. Together they traced how cells were still obtaining cysteine without the standard machinery, ultimately identifying a hidden alternative route: when the usual pathway is blocked, cells can cleave a different bond within cystine — a carbon-sulfur bond adjacent to the standard target — and free usable cysteine from it. The backup had always been there, undetected because no one had thought to search for it.
Schmidt believes the pathway is an ancient adaptation, evolved to help early multicellular organisms survive the electrophilic toxins that pervade the natural world. A second route through chemical stress would have been a powerful survival advantage millions of years ago. But ancient defenses can become modern liabilities. Cancer cells, the researchers suspect, may be activating this same backup system to endure chemotherapy, radiation, and immunotherapy — surviving the assault and regrowing. Selectively disabling the pathway in tumor cells, while leaving healthy cells untouched, could remove a hidden layer of the tumor's resilience and make existing treatments far more effective.
The nine-year journey involved not only senior scientists but undergraduate co-first authors Zoe Seaford and Sydney Austad, along with fellow undergraduates and a doctoral student — a reminder that the work of redefining what cells can do is often built from sustained, collaborative effort across every level of a research team.
For nearly a century, cell biologists operated from a bedrock assumption: mammalian cells cannot survive without at least one functioning disulfide reductase system. This system breaks down cystine, an oxidized form of cysteine, to produce cysteine—an amino acid so essential that cells cannot manufacture it any other way. Without cysteine, cells cannot build proteins, defend themselves against damage, or form the chemical bonds that hold proteins together. The assumption seemed ironclad. No organism had ever been observed living without it.
Then, in 2014, Ed Schmidt's mice refused to cooperate with theory. Schmidt, a genetics professor at Montana State University, had engineered a colony of mice whose liver cells lacked both known disulfide reductase systems—the very machinery that was supposed to be non-negotiable for survival. The mice lived anyway. "This was supposed to be impossible," Schmidt said. The observation gnawed at him. He had previously created separate mouse lines missing one reductase or the other, and the physiological responses he saw in their livers suggested something deeper: perhaps the long-held belief about cellular necessity was simply wrong.
It took seven more years to find the answer. Schmidt's team partnered with Peter Nagy and colleagues at the Hungarian National Institute of Oncology in Budapest, whose analytical expertise proved crucial. Together they traced how cells were still obtaining cysteine despite lacking the standard machinery. What they discovered, published this month in Nature Chemical Biology, was a hidden alternative route. When the usual pathway is blocked, mammalian cells can break a different chemical bond within cystine—a carbon-sulfur bond adjacent to the one the standard system targets. This alternative reaction frees cysteine the cell can use. The backup system had been there all along, invisible because no one had looked for it.
Schmidt theorizes the pathway evolved as an ancient defense mechanism. Many toxins produced by organisms as chemical weapons—electrophilic toxins found in food or the environment—trigger oxidative stress in cells. By providing a second way to survive chemical assault, this backup system likely gave early multicellular organisms a survival advantage millions of years ago. It was a useful adaptation for a world full of poisons.
But useful ancient defenses can become liabilities in modern disease. Cancer cells, Schmidt and his colleagues suspect, may be exploiting this same backup pathway to survive chemotherapy, radiation, and immunotherapy. These treatments work by overwhelming cellular defense systems, but if tumors can activate an alternative survival route, they endure the stress and grow back. The implication is straightforward: if researchers can learn to selectively disable this pathway in cancer cells while leaving healthy cells intact, they might strip away one layer of the tumor's armor, making existing treatments far more effective.
The nine-year journey from impossible mice to a publishable mechanism involved more than senior researchers. Zoe Seaford and Sydney Austad, both undergraduates in Schmidt's lab, served as co-first authors. Martina Serrano Alvarez and Reed Noyd also contributed as undergraduates, and Colin Miller as a doctoral student. The discovery emerged from the kind of sustained, collaborative work that redefines what cells can do—and what we thought we knew about keeping them alive.
Citas Notables
All cells need a constant supply of cysteine to stay alive, yet cysteine is not available outside the cells.— Ed Schmidt, lead researcher
Now that we know cancer cells have this defense mechanism, we might be able to precisely disable it in tumors, making them more susceptible to cancer therapies.— Ed Schmidt
Quieres la nota completa?
Lee el original en ScienceDaily ↗